699 related articles for article (PubMed ID: 23623245)
1. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
[TBL] [Abstract][Full Text] [Related]
2. The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials.
Zaccara G; Perucca P; Loiacono G; Giovannelli F; Verrotti A
Epilepsia; 2013 Jan; 54(1):66-74. PubMed ID: 22779776
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: Results of an indirect comparison meta-analysis of RCTs.
Brigo F; Bragazzi NL; Nardone R; Trinka E
Seizure; 2016 Nov; 42():29-37. PubMed ID: 27710868
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
Abou-Khalil B; Klein P; Shah A; Ryvlin P; Specchio LM; Gama H; Rocha F; Blum D; Grinnell T; Cheng H; Jung J
Epilepsy Res; 2018 Nov; 147():80-86. PubMed ID: 30278294
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
[TBL] [Abstract][Full Text] [Related]
6. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
Ben-Menachem E; Gabbai AA; Hufnagel A; Maia J; Almeida L; Soares-da-Silva P
Epilepsy Res; 2010 May; 89(2-3):278-85. PubMed ID: 20299189
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies.
Gil-Nagel A; Elger C; Ben-Menachem E; Halász P; Lopes-Lima J; Gabbai AA; Nunes T; Falcão A; Almeida L; da-Silva PS
Epilepsia; 2013 Jan; 54(1):98-107. PubMed ID: 22882018
[TBL] [Abstract][Full Text] [Related]
8. A common reference-based indirect comparison meta-analysis of eslicarbazepine versus lacosamide as add on treatments for focal epilepsy.
Brigo F; Trinka E; Bragazzi NL; Nardone R; Milan A; Grillo E
Epilepsy Res; 2016 Nov; 127():12-18. PubMed ID: 27543806
[TBL] [Abstract][Full Text] [Related]
9. Transition from oxcarbazepine to eslicarbazepine acetate: A single center study.
Mäkinen J; Rainesalo S; Peltola J
Brain Behav; 2017 Mar; 7(3):e00634. PubMed ID: 28293474
[TBL] [Abstract][Full Text] [Related]
10. Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results.
Massot A; Vivanco R; Principe A; Roquer J; Rocamora R
Neurologia; 2014 Mar; 29(2):94-101. PubMed ID: 23623701
[TBL] [Abstract][Full Text] [Related]
11. Overnight switching from oxcarbazepine to eslicarbazepine acetate: an observational study.
Schmid E; Kuchukhidze G; Kirschner M; Leitinger M; Höfler J; Rohracher A; Kalss G; Wendling AS; Steinhoff BJ; Trinka E
Acta Neurol Scand; 2017 Apr; 135(4):449-453. PubMed ID: 27444636
[TBL] [Abstract][Full Text] [Related]
12. The tolerability and safety profile of eslicarbazepine acetate in neurological disorders.
Zhu LN; Chen D; Tan G; Wang HJ; Chu S; Liu L
J Neurol Sci; 2020 Jun; 413():116772. PubMed ID: 32217376
[TBL] [Abstract][Full Text] [Related]
13. Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials.
Krauss G; Biton V; Harvey JH; Elger C; Trinka E; Soares da Silva P; Gama H; Cheng H; Grinnell T; Blum D
Epilepsy Res; 2018 Jan; 139():1-8. PubMed ID: 29127848
[TBL] [Abstract][Full Text] [Related]
14. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.
Elger C; Koepp M; Trinka E; Villanueva V; Chaves J; Ben-Menachen E; Kowacs PA; Gil-Nagel A; Moreira J; Gama H; Rocha JF; Soares-da-Silva P
CNS Neurosci Ther; 2017 Dec; 23(12):961-972. PubMed ID: 29030894
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study.
Villanueva V; Serratosa JM; Guillamón E; Garcés M; Giráldez BG; Toledo M; Salas-Puig J; López González FJ; Flores J; Rodríguez-Uranga J; Castillo A; Mauri JA; Camacho JL; López-Gomáriz E; Giner P; Torres N; Palau J; Molins A
Epilepsy Res; 2014 Sep; 108(7):1243-52. PubMed ID: 24908564
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.
Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB
Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures.
Perucca E; Elger C; Halász P; Falcão A; Almeida L; Soares-da-Silva P
Epilepsy Res; 2011 Sep; 96(1-2):132-9. PubMed ID: 21680153
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.
Elger C; Bialer M; Falcão A; Vaz-da-Silva M; Nunes T; Almeida L; Soares-da-Silva P
Epilepsia; 2013 Aug; 54(8):1453-61. PubMed ID: 23758485
[TBL] [Abstract][Full Text] [Related]
19. The adverse event profile of perampanel: meta-analysis of randomized controlled trials.
Zaccara G; Giovannelli F; Cincotta M; Verrotti A; Grillo E
Eur J Neurol; 2013 Aug; 20(8):1204-11. PubMed ID: 23607817
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials.
Biton V; Rogin JB; Krauss G; Abou-Khalil B; Rocha JF; Moreira J; Gama H; Trinka E; Elger CE; Cheng H; Grinnell T; Blum D;
Epilepsy Behav; 2017 Jul; 72():127-134. PubMed ID: 28575761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
